These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Zang C; Zheng Y; Wang Y; Li L Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762 [TBL] [Abstract][Full Text] [Related]
7. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM; Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362 [TBL] [Abstract][Full Text] [Related]
8. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study. Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting. Coşkun F; Çilli A; Hanta İ; Sevinç C; Ödemiş A; Ursavaş A Turk J Med Sci; 2021 Dec; 51(6):3082-3088. PubMed ID: 34565135 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. Ren H; Wang K; Yang H; Gao L Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145 [TBL] [Abstract][Full Text] [Related]
11. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis. Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Song MJ; Moon SW; Choi JS; Lee SH; Lee SH; Chung KS; Jung JY; Kang YA; Park MS; Kim YS; Chang J; Kim SY Sci Rep; 2020 Dec; 10(1):21218. PubMed ID: 33277557 [TBL] [Abstract][Full Text] [Related]
19. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT. Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V Respiration; 2019; 98(1):19-28. PubMed ID: 30965332 [TBL] [Abstract][Full Text] [Related]
20. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Chaudhuri N; Duck A; Frank R; Holme J; Leonard C Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]